Profil
John Bial is currently the Chief Executive Officer at Capsigen, Inc. since 2020.
Prior to this, he worked at Yecuris Corp.
as the President, Chief Executive Officer & Director.
Postes actifs de John Bial
| Sociétés | Poste | Début |
|---|---|---|
Capsigen, Inc.
 Capsigen, Inc. BiotechnologyHealth Technology Capsigen, Inc. is a company based in Vancouver, WA that is developing the next generation of AAV vectors for gene therapy. The company's end-to-end platform uses customized, diverse libraries and proprietary trade™ technology to identify fully functional vectors that meet disease-specific transduction criteria. Capsigen's fit-for-purpose vectors are designed to deliver the highest level of clinical utility in a rapid and high-throughput manner. The company uses data science and directed evolution to build custom AAV capsids to move patients from hope to cured. John Bial has been the CEO of the company since 2020. | Directeur Général | 01/03/2020 |
Anciens postes connus de John Bial
| Sociétés | Poste | Fin |
|---|---|---|
Yecuris Corp.
 Yecuris Corp. BiotechnologyHealth Technology Yecuris Corp. offers drug discovery and development services for liver toxicity. Its products and services include In Vitro, In Vivo, Reagents, and Application Data. The company was founded by Markus Grompe in 2007 and is headquartered in Portland, OR. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Yecuris Corp.
Yecuris Corp. BiotechnologyHealth Technology Yecuris Corp. offers drug discovery and development services for liver toxicity. Its products and services include In Vitro, In Vivo, Reagents, and Application Data. The company was founded by Markus Grompe in 2007 and is headquartered in Portland, OR. | Health Technology |
Capsigen, Inc.
Capsigen, Inc. BiotechnologyHealth Technology Capsigen, Inc. is a company based in Vancouver, WA that is developing the next generation of AAV vectors for gene therapy. The company's end-to-end platform uses customized, diverse libraries and proprietary trade™ technology to identify fully functional vectors that meet disease-specific transduction criteria. Capsigen's fit-for-purpose vectors are designed to deliver the highest level of clinical utility in a rapid and high-throughput manner. The company uses data science and directed evolution to build custom AAV capsids to move patients from hope to cured. John Bial has been the CEO of the company since 2020. | Health Technology |
